EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Renal Ultrasonography Predicts Worsening Renal Function in Patients with Heart Failure Under Tolvaptan Administration

Nobukiyo Tanaka iD, Yoshio Furukawa, Takuya Maeda, Hiroki Ishihara, Kazuhiro Dan, Masanori Teramura, Kei Ichihashi, Tetsuro Takase, Yuya Takahashi, Daichi Tsuzura, Akira Shinoda, Masato Fujii und 3 weitere

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Nobukiyo Tanaka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan. Hauptthemen laut MEDLINE: Antidiuretic Hormone Receptor Antagonists, Glomerular Filtration Rate, Heart Failure, Kidney. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Renal dysfunction in patients with chronic heart failure predicts a poor prognosis. Tolvaptan has a diuretic effect in patients with chronic kidney disease and heart failure without adverse effects on renal function. We aimed to determine the effects of tolvaptan and predictors of worsening renal function in patients with heart failure. Methods and results This post hoc analysis was a sub-analysis of a single-centre prospectively randomized trial on the early and short-term tolvaptan administration. We enrolled 201 participants with decompensated heart failure between January 2014 and March 2019 (early group, n = 104; age: 79.0 ± 12.8 years; late group, n = 97; age: 80.3 ± 10.8 years). Renal ultrasonography was performed before and after the administration of tolvaptan. Urine output and oral water intake significantly increased during tolvaptan administration. The difference between water intake and urine volume increased during tolvaptan administration. Changes in body weight, blood pressure, heart rate, and estimated glomerular filtration rate (eGFR) in both groups were comparable. The changes in peak-systolic velocity (PSV), acceleration time (AT) of the renal arteries, and resistance index were comparable. The changes in PSV and end-diastolic velocity (EDV) of the interlobar arteries increased following tolvaptan administration (Δmax PSV: 0.0 ± 14.8 cm/s before tolvaptan vs. 5.6 ± 15.7 cm/s after tolvaptan, P = 0.002; Δmean PSV: 0.4 ± 12.3 vs. 4.9 ± 12.7 cm/s, P = 0.002; Δmax EDV: −0.2 ± 3.5 vs. 1.4 ± 4.0 cm/s, P = 0.001; Δmean EDV: −0.0 ± 3.1 vs. 1.1 ± 3.4 cm/s, P = 0.003). The renal artery AT was negatively correlated with the eGFR (Δmax AT: beta = −0.2354, P = 0.044; Δmean AT: beta = −0.2477, P = 0.035).

Conclusions

Tolvaptan increased the PSV and EDV of the interlobar artery, which may mean tolvaptan increased renal blood flow. The renal artery AT may be a surrogate for worsening renal function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidiuretic Hormone Receptor AntagonistsGlomerular Filtration RateHeart FailureKidneyTolvaptanUltrasonographyAgedAged, 80 and overFemaleHumansMaleDisease ProgressionFollow-Up StudiesPrognosisProspective StudiesRenal Insufficiency, ChronicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Acceleration timeEnd‐diastolic velocityHeart failurePeak‐systolic velocityRenal ultrasonographyTolvaptan

Substanzen

Antidiuretic Hormone Receptor AntagonistsTolvaptan

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan.

ORCID-Profile: Nobukiyo Tanaka

Zitieren

APA

Tanaka, N., Furukawa, Y., Maeda, T., Ishihara, H., Dan, K., Teramura, M., Ichihashi, K., Takase, T., Takahashi, Y., Tsuzura, D., Shinoda, A., Fujii, M., Okada, H., Itabashi, F., & Teramoto, T. (2024). Renal Ultrasonography Predicts Worsening Renal Function in Patients with Heart Failure Under Tolvaptan Administration. ESC Heart Failure. https://doi.org/10.1002/ehf2.14740

Vancouver

Tanaka N, Furukawa Y, Maeda T, Ishihara H, Dan K, Teramura M, et al. Renal Ultrasonography Predicts Worsening Renal Function in Patients with Heart Failure Under Tolvaptan Administration. ESC Heart Failure. 2024. doi:10.1002/ehf2.14740

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Nobukiyo and Furukawa, Yoshio and Maeda, Takuya and Ishihara, Hiroki and Dan, Kazuhiro and Teramura, Masanori and Ichihashi, Kei and Takase, Tetsuro and Takahashi, Yuya and Tsuzura, Daichi and Shinoda, Akira and Fujii, Masato and Okada, Hisashi and Itabashi, Fumiharu and Teramoto, Tomohiko},
  title = {Renal Ultrasonography Predicts Worsening Renal Function in Patients with Heart Failure Under Tolvaptan Administration},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14740}
}
Kostenlos starten →